clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2024-102-7-510-517clinmed-879Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESСовременный взгляд на клиническое фенотипирование хронической обструктивной болезни легкихModern view on clinical phenotyping of chronic obstructive pulmonary diseasehttps://orcid.org/0000-0002-0273-4388ПономареваИ. Б.PonomarevaI. B.

Пономарева Ирина Борисовна — канд. мед. наук, доцент, доцент кафедры факультетской терапии имени профессора В.Я. Гармаша

Рязань

Irina B. Ponomareva — Candidate of Medical Sciences, Associate Professor, Associate Professor of the Department of Faculty Therapy named after Professor V.Y. Garmash

Ryazan

docib@yandex.ruhttps://orcid.org/0000-0002-4445-4480ГлотовС. И.GlotovS. I.

Глотов Сергей Иванович — канд. мед. наук, доцент, доцент кафедры факультетской терапии имени профессора В.Я. Гармаша

Рязань

Sergey I. Glotov — Candidate of Medical Sciences, Associate Professor, Associate Professor of the Department of Faculty Therapy named after Professor V.Y. Garmash

Ryazan

https://orcid.org/0000-0001-8693-4696УрясьевО. М.UryasyevO. M.

Урясьев Олег Михайлович — д-р мед. наук, профессор, заведующий кафедрой факультетской терапии имени профессора В.Я. Гармаша

Рязань

Oleg M. Uryasyev — Doctor of Medical Sciences, Professor, Head of the Department of Faculty Therapy named after Professor V.Y. Garmash

Ryazan

https://orcid.org/0000-0003-0945-0772КоршуноваЛ. В.KorshunovaL. V.

Коршунова Людмила Владимировна — канд. мед. наук, доцент, доцент кафедры факультетской терапии имени профессора В.Я. Гармаша

Рязань

Lyudmila V. Korshunova — Candidate of Medical Sciences, Associate Professor, Associate Professor of the Department of Faculty Therapy named after Professor V.Y. Garmash

Ryazan

https://orcid.org/0000-0002-2770-3414ЕрмачковаА. Н.ErmachkovaA. N.

Ермачкова Анна Николаевна — врач терапевт

Рязань

Anna N. Ermachkova — general practitioner of the State Medical Institution of the Ryazan region Polyclinic No. 12

Ryazan

ФГБОУ ВО «Рязанский государственный медицинский университет имени академика И.П. Павлова» Минздрава РоссииРоссияRyazan State Medical University named after Academician I.P. Pavlov of the Ministry of Healthcare of RussiaRussian Federation2024211120241027510–517Copyright © Пономарева И.Б., Глотов С.И., Урясьев О.М., Коршунова Л.В., Ермачкова А.Н., 20242024Пономарева И.Б., Глотов С.И., Урясьев О.М., Коршунова Л.В., Ермачкова А.Н.Ponomareva I.B., Glotov S.I., Uryasyev O.M., Korshunova L.V., Ermachkova A.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/879

Хроническая обструктивная болезнь легких (ХОБЛ) является гетерогенным и мультисистемным заболеванием с множественными фенотипами и прогрессирующим увеличением заболеваемости и смертности. В статье изложен обзор современных данных по идентификации, характеристике и особенностям терапии наиболее распространенных фенотипов заболевания. Проведен обзор литературы в медицинских ресурсах PubMed, Google Scholar, UpToDate, затрагивающих вопросы фенотипирования при ХОБЛ.

Chronic obstructive pulmonary disease (COPD) is a heterogeneous and multisystem disease with multiple phenotypes and a progressive increase in morbidity and mortality. This article provides a review of the current data on the identification, characterization, and features of therapy for the most common phenotypes of the disease. A literature review was conducted using medical resources such as PubMed, Google Scholar, and UpToDate, addressing issues related to phenotyping in COPD.

хроническая обструктивная болезнь легкихфенотипыклинические исследованияклинические рекомендациифенотип-специфическая терапияchronic obstructive pulmonary diseasephenotypesclinical studiesclinical guidelinesphenotype-specific therapyReferencesGlobal Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2023 Report. [Electronic resource]. URL: https://goldcopd.org/2023-gold-report-2/Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2023 Report. [Electronic resource]. URL: https://goldcopd.org/2023-gold-report-2/Министерство здравоохранения Российской Федерации. Хроническая обструктивная болезнь легких: Клинические рекомендации. URL: https://spulmo.ru/upload/kr/HOBL_2023_draft.pdfMinistry of Health of the Russian Federation [Chronic obstructive pulmonary disease: Clinical guidelines. (I n Russian)]. [Electronic resource]. URL: https://spulmo.ru/upload/kr/HOBL_2023_draft.pdfАвдеев С.Н., Лещенко И.В., Айсанов З.Р. Новая концепция и алгоритм ведения пациентов с хронической обструктивной болезнью легких. Пульмонология. 2023;33(5):587–594.Avdeev S.N., Leshchenko I.V., Aisanov Z.R. [New concept and algorithm for the management of patients with chronic obstructive pulmonary disease. Pul’monologiya. 2023;33(5):587–594. (In Russian)]. DOI: 10.18093/0869-0189-2023-33-5-587-594Чучалин А.Г., Авдеев С.Н., Айсанов З.Р., Белевский А.С., Лещенко И.В., Овчаренко С.И., Шмелев Е.И. Хроническая обструктивная болезнь легких: федеральные клинические рекомендации по диагностике и лечению. Пульмонология. 2022;32(3):356– 392.Chuchalin A.G., Avdeev S.N., Aisanov Z.R., Belevskiy A.S., Leshchenko I.V., Ovcharenko S.I., Shmelev E.I. [Federal guidelines on diagnosis and treatment of bronchial asthma. Pul’monologiya. 2022;32(3):393–447. (In Russian)]. DOI: 10.18093/0869-0189-2022-32-3-393-447Weatherall M., Travers J., Shirtcliff e P.M., Marsh S.E., Williams M.V., Nowitz M.R., Aldington S., Beasley R. Distinct clinical phenotypes of airways disease defi ned by cluster analysis. Eur. Respir. J. 2009;34(4):812–8. DOI: 10.1183/09031936.00174408Weatherall M., Travers J., Shirtcliff e P.M., Marsh S.E., Williams M.V., Nowitz M.R., Aldington S., Beasley R. Distinct clinical phenotypes of airways disease defi ned by cluster analysis. Eur. Respir. J. 2009;34(4):812–8. DOI: 10.1183/09031936.00174408Han M.K., Agusti A., Calverley P.M. Celli B.R., Criner G., Curtis J.L., Fabbri L.M., Goldin J.G., Jones P.W., Macnee W., Make B.J., Rabe K.F., Rennard S.I., Sciurba F.C., Silverman E.K., Vestbo J., Washko G.R, Wouters E. F.M., Martinez F.J. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am. J. Respir. Crit. Care Med. 2010;182(5):598–604. DOI: 10.1164/rccm.200912-1843CCHan M.K., Agusti A., Calverley P.M. Celli B.R., Criner G., Curtis J.L., Fabbri L.M., Goldin J.G., Jones P.W., Macnee W., Make B.J., Rabe K.F., Rennard S.I., Sciurba F.C., Silverman E.K., Vestbo J., Washko G.R, Wouters E. F.M., Martinez F.J. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am. J. Respir. Crit. Care Med. 2010;182(5):598–604. DOI: 10.1164/rccm.200912-1843CCVestbo J. COPD: defi nition and phenotypes. Clin. Chest. Med. 2014;35(1):1–6. DOI: 10.1016/j.ccm.2013.10.010Vestbo J. COPD: defi nition and phenotypes. Clin. Chest. Med. 2014;35(1):1–6. DOI: 10.1016/j.ccm.2013.10.010Murakami Y., Minakata Y., Kato M., Sasaki S., Azuma Y., Kawabe K., Ono H. Determinants of Activity Phenotype in Patients With Chronic Obstructive Pulmonary Disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2023;18:1919–1929. DOI: 10.2147/COPD.S421755Murakami Y., Minakata Y., Kato M., Sasaki S., Azuma Y., Kawabe K., Ono H. Determinants of Activity Phenotype in Patients With Chronic Obstructive Pulmonary Disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2023;18:1919–1929. DOI: 10.2147/COPD.S421755Guerreiro I., Soccal P.M. Les phénotypes de la BPCO [COPD and phenotypes]. Rev. Med. Suisse. 2019;15(671):2082–2086. PMID: 31742938.Guerreiro I., Soccal P.M. Les phénotypes de la BPCO [COPD and phenotypes]. Rev. Med. Suisse. 2019;15(671):2082–2086. PMID: 31742938.Speizer F.E., Ware J.H. Exploring diff erent phenotypes of COPD. N. Engl. J. Med. 2015;373(2):185–6. DOI: 10.1056/NEJMe1503888Speizer F.E., Ware J.H. Exploring diff erent phenotypes of COPD. N. Engl. J. Med. 2015;373(2):185–6. DOI: 10.1056/NEJMe1503888Wu J.J., Xu H.R., Zhang Y.X., Li Y.X., Yu H.Y., Jiang L.D., Wang C.X., Han M. The characteristics of the frequent exacerbator with chronic bronchitis phenotype and non-exacerbator phenotype in patients with chronic obstructive pulmonary disease: a meta-analysis and system review. BMC Pulm. Med. 2020;20(1):103. DOI: 10.1186/s12890-020-1126-xWu J.J., Xu H.R., Zhang Y.X., Li Y.X., Yu H.Y., Jiang L.D., Wang C.X., Han M. The characteristics of the frequent exacerbator with chronic bronchitis phenotype and non-exacerbator phenotype in patients with chronic obstructive pulmonary disease: a meta-analysis and system review. BMC Pulm. Med. 2020;20(1):103. DOI: 10.1186/s12890-020-1126-xGolpe R., Suárez-Valor M., Martín-Robles I., Sanjuán-López P., Cano-Jiménez E., Castro-Añón O., de Llano L. A.P. Mortality in COPD patients according to clinical phenotypes. Int. J. Chron. Obstruct. Pulmon. Dis. 2018;13:1433–1439. DOI: 10.2147/COPD.S159834Golpe R., Suárez-Valor M., Martín-Robles I., Sanjuán-López P., Cano-Jiménez E., Castro-Añón O., de Llano L. A.P. Mortality in COPD patients according to clinical phenotypes. Int. J. Chron. Obstruct. Pulmon. Dis. 2018;13:1433–1439. DOI: 10.2147/COPD.S159834Трушенко Н.В., Сопова М.И., Сопова В.И. Фенотипы хронической обструктивной болезни легких — путь к персонифицированной терапии. Практическая пульмонология. 2019;(3):32–39Trushenko N.V., Sopova M.I., Sopova V.I. Chronic Obstructive Pulmonary Disease Phenotypes — the Way to Personaliz ed Therapy. Practical pulmonology. 2019;(3):32–39. (In Russian)].Alabi F.O., Alkhateeb H.A., DeBarros K.M., Benel B.P.S., Sanchez-Martez R.L., Zeper M.L., Ismail R.A., Umeh F., Medina-Villanueva N. The heterogeneity of COPD patients in a community-based practice and the inadequacy of the global initiative for chronic obstructive lung disease criteria: a real-world experience. Chronic. Obstr. Pulm. Dis. 2021;8(3):396–407. DOI: 10.15326/jcopdf.2021.0229Alabi F.O., Alkhateeb H.A., DeBarros K.M., Benel B.P.S., Sanchez-Martez R.L., Zeper M.L., Ismail R.A., Umeh F., Medina-Villanueva N. The heterogeneity of COPD patients in a community-based practice and the inadequacy of the global initiative for chronic obstructive lung disease criteria: a real-world experience. Chronic. Obstr. Pulm. Dis. 2021;8(3):396–407. DOI: 10.15326/jcopdf.2021.0229Guerreiro I., Soccal P.M. COPD and phenotypes. Rev. Med. Suisse. 2019;15(671):2082–2086.Guerreiro I., Soccal P.M. COPD and phenotypes. Rev. Med. Suisse. 2019;15(671):2082–2086.Barnes P.J. Endo-phenotyping of COPD patients. Expert Rev. Respir. Med. 2021;15(1):27–37. DOI: 10.1080/17476348.2020.1804364Barnes P.J. Endo-phenotyping of COPD patients. Expert Rev. Respir. Med. 2021;15(1):27–37. DOI: 10.1080/17476348.2020.1804364Barnes P.J. Infl ammatory endotypes in COPD. Allergy. 2019;74(7):1249–1256. DOI: 10.1111/all.13760Barnes P.J. Infl ammatory endotypes in COPD. Allergy. 2019;74(7):1249–1256. DOI: 10.1111/all.13760Miravitlles M., Soler-Cataluña J.J., Calle M., Molina J., Almagro P., Quintano J.A., Riesco J.A., Trigueros J.A., Piñera P., Simón A., López-Campos J.L., Soriano J.B., Ancochea J. Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable. Archivos de Bronconeumología, 2012;48(7),247–257. DOI: 10.1016/j.arbres.2012.04.001Miravitlles M., Soler-Cataluña J.J., Calle M., Molina J., Almagro P., Quintano J.A., Riesco J.A., Trigueros J.A., Piñera P., Simón A., López-Campos J.L., Soriano J.B., Ancochea J. Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable. Archivos de Bronconeumología, 2012;48(7),247–257. DOI: 10.1016/j.arbres.2012.04.001Miravitlles M., Vogelmeier C., Roche N., Halpin D., Cardoso J., Chuchalin A.G., Kankaanranta H., Sandström T., Śliwiński P., Zatloukal J., Blasi F. A review of national guidelines for management of COPD in Europe. Eur. Respir. J. 2016;47(2):625–37. DOI: 10.1183/13993003.01170-2015Miravitlles M., Vogelmeier C., Roche N., Halpin D., Cardoso J., Chuchalin A.G., Kankaanranta H., Sandström T., Śliwiński P., Zatloukal J., Blasi F. A review of national guidelines for management of COPD in Europe. Eur. Respir. J. 2016;47(2):625–37. DOI: 10.1183/13993003.01170-2015Lazic Z., Stankovic I., Milenkovic B., Zvezdin B., Zvezdin B., Hromis S., Jankovic S., Cupurdija V. Characteristics of COPD Phenotypes in Serbia. Int. J. Chron. Obstruct. Pulmon. Dis. 2021;16:643–654. DOI: 10.2147/COPD.S300693Lazic Z., Stankovic I., Milenkovic B., Zvezdin B., Zvezdin B., Hromis S., Jankovic S., Cupurdija V. Characteristics of COPD Phenotypes in Serbia. Int. J. Chron. Obstruct. Pulmon. Dis. 2021;16:643–654. DOI: 10.2147/COPD.S300693Snider G.L. Chronic obstructive pulmonary disease: a defi nition and implications of structural determinants of airfl ow obstruction for epidemiology. Am. Rev. Respir. Dis. 1989;140(3Pt2):S3–8. DOI: 10.1164/ajrccm/140.3_Pt_2.S3Snider G.L. Chronic obstructive pulmonary disease: a defi nition and implications of structural determinants of airfl ow obstruction for epidemiology. Am. Rev. Respir. Dis. 1989;140(3Pt2):S3–8. DOI: 10.1164/ajrccm/140.3_Pt_2.S3Yousuf A., McAuley H., Elneima O., Brightling C.E. The diff erent phenotypes of COPD. Br. Med. Bull. 2021;137(1):82–97. DOI: 10.1093/bmb/ldaa043Yousuf A., McAuley H., Elneima O., Brightling C.E. The diff erent phenotypes of COPD. Br. Med. Bull. 2021;137(1):82–97. DOI: 10.1093/bmb/ldaa043Leung J.M., Obeidat M., Sadatsafavi M., Sin D.D. Introduction to precision medicine in COPD. Eur. Respir. J. 2019;53(4):1802460. DOI: 10.1183/13993003.02460-2018Leung J.M., Obeidat M., Sadatsafavi M., Sin D.D. Introduction to precision medicine in COPD. Eur. Respir. J. 2019;53(4):1802460. DOI: 10.1183/13993003.02460-2018Miravitlles M., Soler-Cataluña J.J., Calle M., Soriano J.B. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur. Respir. J. 2013;41(6):1252–6. DOI: 10.1183/09031936.00118912Miravitlles M., Soler-Cataluña J.J., Calle M., Soriano J.B. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur. Respir. J. 2013;41(6):1252–6. DOI: 10.1183/09031936.00118912Siafakas N., Corlateanu A., Fouka E. Phenotyping Before Starting Treatment in COPD? COPD. 2017;14(3):367–374. DOI: 10.1080/15412555.2017.1303041Siafakas N., Corlateanu A., Fouka E. Phenotyping Before Starting Treatment in COPD? COPD. 2017;14(3):367–374. DOI: 10.1080/15412555.2017.1303041Garcia-Aymerich J., Gómez F.P., Benet M., Farrero E., Basagaña X., Gayete À., Paré C., Freixa X., Ferrer J., Ferrer A., Roca J., Gáldiz J.B., Sauleda J., Monsó E., Gea J., Barberà J.A., Agustí À., Antó J.M. Identifi cation and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax. 2011;66(5):430–7. DOI: 10.1136/thx.2010.154484Garcia-Aymerich J., Gómez F.P., Benet M., Farrero E., Basagaña X., Gayete À., Paré C., Freixa X., Ferrer J., Ferrer A., Roca J., Gáldiz J.B., Sauleda J., Monsó E., Gea J., Barberà J.A., Agustí À., Antó J.M. Identifi cation and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax. 2011;66(5):430–7. DOI: 10.1136/thx.2010.154484Rizzi A., Amari G., Pivetti F., Delcanale M., Amadei F., Pappani A., Fornasari L., Villetti G., Marchini G., Pisano A.R., Pitozzi V., Pittelli M.G., Trevisani M., Salvadori M., Cenacchi V., Fioni A., Puccini P., Civelli M., Patacchini R., Baker-Glenn C., Van de Poël H., Blackaby W., Nash K., Armani E. Optimization of M3 Antagonist-PDE4 Inhibitor (MAPI) Dual Pharmacology Molecules for the Treatment of COPD. J. Med. Chem. 2023;66(16):11476–11497. DOI: 10.1021/acs.jmedchem.3c01012Rizzi A., Amari G., Pivetti F., Delcanale M., Amadei F., Pappani A., Fornasari L., Villetti G., Marchini G., Pisano A.R., Pitozzi V., Pittelli M.G., Trevisani M., Salvadori M., Cenacchi V., Fioni A., Puccini P., Civelli M., Patacchini R., Baker-Glenn C., Van de Poël H., Blackaby W., Nash K., Armani E. Optimization of M3 Antagonist-PDE4 Inhibitor (MAPI) Dual Pharmacology Molecules for the Treatment of COPD. J. Med. Chem. 2023;66(16):11476–11497. DOI: 10.1021/acs.jmedchem.3c01012Cazzola M., Calzetta L., Page C., Jardim J., Chuchalin A.G., Rogliani P., Matera M.G. Infl uence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur. Respir. Rev. 2015;24(137):451–461. DOI: 10.1183/16000617.00002215Cazzola M., Calzetta L., Page C., Jardim J., Chuchalin A.G., Rogliani P., Matera M.G. Infl uence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur. Respir. Rev. 2015;24(137):451–461. DOI: 10.1183/16000617.00002215Poole P., Black P.N., Cates C.J. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012;(8):CD001287. DOI: 10.1002/14651858.cd001287. pub4Poole P., Black P.N., Cates C.J. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012;(8):CD001287. DOI: 10.1002/14651858.cd001287. pub4Zeng Z., Yang D., Huang X., Xiao Z. Eff ect of carbocisteine on patients with COPD: a systematic review and meta-analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2017;12:2277–2283. DOI: 10.2147/COPD.S140603Zeng Z., Yang D., Huang X., Xiao Z. Eff ect of carbocisteine on patients with COPD: a systematic review and meta-analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2017;12:2277–2283. DOI: 10.2147/COPD.S140603Dal Negro R., Wedzicha J., Iversen M. Fontana G., Page C., Cicero A.F., Pozzi E., Calverley P. M.A. Eff ect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur. Respir. J. 2017;50(4):1700711. DOI: 10.1183/13993003.00711-2017Dal Negro R., Wedzicha J., Iversen M. Fontana G., Page C., Cicero A.F., Pozzi E., Calverley P. M.A. Eff ect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur. Respir. J. 2017;50(4):1700711. DOI: 10.1183/13993003.00711-2017Donath E., Chaudhry A., Hernandez-Aya L.F., Lit L. A meta-analysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with Chronic Obstructive Pulmo- nary Disease. Respir. Med. 2013;107(9):1385–1392. DOI: 10.1016/j.rmed.2013.05.004Donath E., Chaudhry A., Hernandez-Aya L.F., Lit L. A meta-analysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with Chronic Obstructive Pulmo- nary Disease. Respir. Med. 2013;107(9):1385–1392. DOI: 10.1016/j.rmed.2013.05.004Albert R.K., Connett J., Bailey W.C., Richard Casaburi, Cooper J.A.D., Criner G.J., Curtis J.L., Dransfi eld M.T., Han M.K., Lazarus S.C., Make B., Marchetti N., Martinez F.J., Madinger N.E., McEvoy C., Niewoehner D.E., Porsasz J., Price C.S., Reilly J., Scanlon P.D., Sciurba F.C., Scharf S.M., Washko G.R., Woodruff P.G., Anthonisen N. R. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 2011;365(8):689–698. DOI: 10.1056/nejmoa1104623Albert R.K., Connett J., Bailey W.C., Richard Casaburi, Cooper J.A.D., Criner G.J., Curtis J.L., Dransfi eld M.T., Han M.K., Lazarus S.C., Make B., Marchetti N., Martinez F.J., Madinger N.E., McEvoy C., Niewoehner D.E., Porsasz J., Price C.S., Reilly J., Scanlon P.D., Sciurba F.C., Scharf S.M., Washko G.R., Woodruff P.G., Anthonisen N. R. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 2011;365(8):689–698. DOI: 10.1056/nejmoa1104623Suissa S., Ernst P. Observational studies of inhaled corticosteroid effectiveness in COPD: lessons learned. Chest. 2018;154(2):257–265. DOI: 10.1016/j.chest.2018.04.006Suissa S., Ernst P. Observational studies of inhaled corticosteroid effectiveness in COPD: lessons learned. Chest. 2018;154(2):257–265. DOI: 10.1016/j.chest.2018.04.006Kendzerska T., Aaron S.D., To T., Licskai C., Stanbrook M., Vozoris N.T., Hogan M.E., Tan W.C., Bourbeau J., Gershon A.S. Eff ectiveness and safety of inhaled corticosteroids in older individuals with chronic obstructive pulmonary disease and/or asthma. A population study. Ann. Am. Thorac. Soc. 2019;16(10):1252–1262. DOI: 10.1513/AnnalsATS.201902-126OCKendzerska T., Aaron S.D., To T., Licskai C., Stanbrook M., Vozoris N.T., Hogan M.E., Tan W.C., Bourbeau J., Gershon A.S. Eff ectiveness and safety of inhaled corticosteroids in older individuals with chronic obstructive pulmonary disease and/or asthma. A population study. Ann. Am. Thorac. Soc. 2019;16(10):1252–1262. DOI: 10.1513/AnnalsATS.201902-126OCWhite P., Thorntoh H., Pinnock H., Georgopoulou S., Booth H.P. Overtreatment of COPD with inhaled corticosteroids – implications for safety and costs: cross-sectional observational study. PLoS One. 2013;8(10):e75221. DOI: 10.1371/journal.pone.0075221White P., Thorntoh H., Pinnock H., Georgopoulou S., Booth H.P. Overtreatment of COPD with inhaled corticosteroids – implications for safety and costs: cross-sectional observational study. PLoS One. 2013;8(10):e75221. DOI: 10.1371/journal.pone.0075221Somayaji R., Chalmers J.D. Just breathe: a review of sex and gender in chronic lung disease. Eur. Respir. Rev. 2022;31(163):210111. DOI: 10.1183/16000617.0111-2021Somayaji R., Chalmers J.D. Just breathe: a review of sex and gender in chronic lung disease. Eur. Respir. Rev. 2022;31(163):210111. DOI: 10.1183/16000617.0111-2021Nikolaou V., Massaro S., Fakhimi M., Stergioulas L., Price D. COPD phenotypes and machine learning cluster analysis: a systematic review and future research agenda. Respir. Med. 2020;171:106093. DOI: 10.1016/j.rmed.2020.106093Nikolaou V., Massaro S., Fakhimi M., Stergioulas L., Price D. COPD phenotypes and machine learning cluster analysis: a systematic review and future research agenda. Respir. Med. 2020;171:106093. DOI: 10.1016/j.rmed.2020.106093Ghebre M.A., Pang P.H., Diver S., Desai D., Bafadhel M., Haldar K., Kebadze T., Cohen S., Newbold P., Rapley L., Woods J., Rugman P., Pavord I.D., Johnston S.L., Barer M., May R.D., Brightling C.E. Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profi les. J. Allergy Clin. Immunol. 2018;141(6):2027–2036.e12. DOI: 10.1016/j.jaci.2018.04.013Ghebre M.A., Pang P.H., Diver S., Desai D., Bafadhel M., Haldar K., Kebadze T., Cohen S., Newbold P., Rapley L., Woods J., Rugman P., Pavord I.D., Johnston S.L., Barer M., May R.D., Brightling C.E. Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profi les. J. Allergy Clin. Immunol. 2018;141(6):2027–2036.e12. DOI: 10.1016/j.jaci.2018.04.013Овчаренко С.И. Фенотипы больных хронической обструктивной болезнью легких и исследование ECLIPSE: первые результаты. Пульмонология. 2011;3:113–117.Ovcharenko S.I. Phenotypes of chronic obstructive pulmonary disease and the ECLIPSE study: preliminary results. Pul’monologiya. 2011;3:113–117.(In Russian)].Vestbo J., Anderson W., Coxson H.O., Crim C., Dawber F., Edwards L., Hagan G., Knobil K., Lomas D.A., MacNee W., Silverman E.K., Tal-Singer R. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoint (ECLIPSE). Eur. Respir. J. 2008;31:869–873. DOI: 10.1183/09031936.00111707Vestbo J., Anderson W., Coxson H.O., Crim C., Dawber F., Edwards L., Hagan G., Knobil K., Lomas D.A., MacNee W., Silverman E.K., Tal-Singer R. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoint (ECLIPSE). Eur. Respir. J. 2008;31:869–873. DOI: 10.1183/09031936.00111707Hurst J.R., Vestbo J., Anzueto A., Locantore N., Müllerova H., Tal-Singer R., Miller B., Lomas D.A., Agusti A., Macnee W., Calverley P., Rennard S., Wouters E.F. M., Wedzicha J.A. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010;363:1128–1138. DOI: 10.1056/NEJMoa0909883Hurst J.R., Vestbo J., Anzueto A., Locantore N., Müllerova H., Tal-Singer R., Miller B., Lomas D.A., Agusti A., Macnee W., Calverley P., Rennard S., Wouters E.F. M., Wedzicha J.A. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010;363:1128–1138. DOI: 10.1056/NEJMoa0909883Han M.K., Kazerooni E.A., Lynch D.A., Liu L.X., Murray S., Curtis J.L., Criner G.J., Kim V., Bowler R.P., Hanania N.A., Anzue to A.R., Make B. J., Hokanson J.E., Crapo J.D., Silverman E.K., Martinez F.J., Washko G.R. Chronic Obstructive Pulmonary Disease Exacerbations in the COPDGene Study: Associated Radiologic Phenotypes. Radiology. 2011;261(1):274–82. DOI: 10.1148/radiol.11110173Han M.K., Kazerooni E.A., Lynch D.A., Liu L.X., Murray S., Curtis J.L., Criner G.J., Kim V., Bowler R.P., Hanania N.A., Anzue to A.R., Make B. J., Hokanson J.E., Crapo J.D., Silverman E.K., Martinez F.J., Washko G.R. Chronic Obstructive Pulmonary Disease Exacerbations in the COPDGene Study: Associated Radiologic Phenotypes. Radiology. 2011;261(1):274–82. DOI: 10.1148/radiol.11110173Nishimura M., Makita H., Nagai K., Konno S., Nasuhara Y., Hasegawa M., Shimizu K., Betsuyaku T., Ito Y.M., Fuke S., Igarashi T., Akiyama Y., Ogura S. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012;185(1):44–52. DOI: 0.1164/rccm.201106-0992OCNishimura M., Makita H., Nagai K., Konno S., Nasuhara Y., Hasegawa M., Shimizu K., Betsuyaku T., Ito Y.M., Fuke S., Igarashi T., Akiyama Y., Ogura S. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012;185(1):44–52. DOI: 0.1164/rccm.201106-0992OCKume H., Hojo M., Hashimoto N. Eosinophil Infl ammation and Hyperresponsiveness in the Airways as Phenotypes of COPD, and Usefulness of Inhaled Glucocorticosteroids. Front Pharmacol. 2019;25:10:765. DOI: 10.3389/fphar.2019.00765Kume H., Hojo M., Hashimoto N. Eosinophil Infl ammation and Hyperresponsiveness in the Airways as Phenotypes of COPD, and Usefulness of Inhaled Glucocorticosteroids. Front Pharmacol. 2019;25:10:765. DOI: 10.3389/fphar.2019.00765Huang W.C., Tsai Y.H., Wei Y.F., Kuo P.H., Tao C.W., Cheng S.L., Lee C.H., Wu Y.K., Chen N.H., Hsu W.H., Hsu J.Y., Wang C.C., Lin M.S. Wheezing, a signifi cant clinical phenotype of COPD: experience from the Taiwan Obstructive Lung Disease Study. Int. J. Chron. Obstruct. Pulmon. Dis. 2015;10:2121–2126. [Electronic resource]. URL: https://www.semanticscholar.org/reader/4a7b7f49b-0caeba6195bd3566568f60157cd030aHuang W.C., Tsai Y.H., Wei Y.F., Kuo P.H., Tao C.W., Cheng S.L., Lee C.H., Wu Y.K., Chen N.H., Hsu W.H., Hsu J.Y., Wang C.C., Lin M.S. Wheezing, a signifi cant clinical phenotype of COPD: experience from the Taiwan Obstructive Lung Disease Study. Int. J. Chron. Obstruct. Pulmon. Dis. 2015;10:2121–2126. [Electronic resource]. URL: https://www.semanticscholar.org/reader/4a7b7f49b-0caeba6195bd3566568f60157cd030aGonzález-García M., Torres-Duque C. Wood smoke COPD: a new description of a COPD phenotype? Eur. Respir. J. 2014;44(1):261–2. DOI: 10.1183/09031936.00222913González-García M., Torres-Duque C. Wood smoke COPD: a new description of a COPD phenotype? Eur. Respir. J. 2014;44(1):261–2. DOI: 10.1183/09031936.00222913Torres-Duque C.A., García-Rodriguez M.C., González-García M. Is chronic obstructive pulmonary disease caused by wood smoke a diff erent phenotype or a diff erent entity? Arch. Bronconeumol. 2016;52(8):425–31. DOI: 10.1016/j.arbres.2016.04.004Torres-Duque C.A., García-Rodriguez M.C., González-García M. Is chronic obstructive pulmonary disease caused by wood smoke a diff erent phenotype or a diff erent entity? Arch. Bronconeumol. 2016;52(8):425–31. DOI: 10.1016/j.arbres.2016.04.004Ji W., Lim M.N., Bak S.H., Hong S.H., Han S.S., Lee S.J., Kim W.J., Hong Y. Diff erences in chronic obstructive pulmonary disease phenotypes between non-smokers and smokers. Clin. Respir. J. 2018;12(2):66–67. DOI: 10.1111/crj.12577Ji W., Lim M.N., Bak S.H., Hong S.H., Han S.S., Lee S.J., Kim W.J., Hong Y. Diff erences in chronic obstructive pulmonary disease phenotypes between non-smokers and smokers. Clin. Respir. J. 2018;12(2):66–67. DOI: 10.1111/crj.12577Perret J.L, Abramson M.J. Biomass smoke COPD: A phenotype or a diff erent disease? Respirology. 2018;23(2):124–125. DOI: 10.1111/resp.13227Perret J.L, Abramson M.J. Biomass smoke COPD: A phenotype or a diff erent disease? Respirology. 2018;23(2):124–125. DOI: 10.1111/resp.13227Овсянников Е.С., Будневский А.В., Шкатова Я.С. Оценка эффективности тренировки дыхательной мускулатуры у больных хронической обструктивной болезнью легких и ожирением. Российский медико-биологический вестник имени академика И.П. Павлова. 2019;27(3):367–374.Ovsyannikov E.S., Budnevsky A.V., Shkatova Ya.S. Evaluation of respiratory muscle training eff ectiveness in patients with chronic obstructive pulmonary disease and obesity. I.P. Pavlov Russian Medical Biological Herald. 2019;27(3):367–74. (In Russian)]. DOI: 10.23888/PAVLOVJ2019273367-374.Котляров С.Н., Мотынга К.А. Физическая слабость как фенотип ХОБЛ. Наука молодых (Eruditio Juvenium). 2020;8(4):599–608. [Kotlyarov S.N., Motynga K.A. Physical weakness as COPD phenotype. Science of the young (Eruditio Juvenium). 2020;8(4):599–608. (In Russian)]. DOI: 10.23888/HMJ202084599-608Абросимов В.Н., Перегудова Н.Н., Косяков А.В. Оценка функциональных показателей дыхательной системы у пациентов с хронической обструктивной болезнью легких при проведении 6-минутного шагового теста. Наука молодых (Eruditio Juvenium). 2019;7(3):323–331.Abrosimov V.N., Peregudova N.N., Kosyakov A.V. Evaluation of functional parameters of respiratory system in patients with chronic obstructive pulmonary disease in 6-minute walking test. Science of the young (Eruditio Juvenium). 2019;7(3):323–31. (In Russian)]. DOI: 10.23888/HMJ201973323-331Mesquita R., Spina G., Pitta F., Donaire-Gonzalez D., Deering B.M., Patel M.S. , Mitchell K.E., Alison J., van Gestel A.J., Zogg S., Gagnon Ph., Abascal-Bolado B., Vagaggini B., Garcia-Ayme rich J., Jenkins S.C., Romme E.A., Kon S. S., Albert P.S., Waschki B., Shrikrishna D., Singh S.J., Hopkinson N.S., Miedinger D., Benzo R.P., Maltais F., Paggiaro P., McKeough Z.J., Polkey M.I., Hill K., Man W.D-C., Clarenbach C. F., Hernandes N.A., Savi D., Wootton S., Furlanetto K.C., Cindy Ng L.W., Vaes A.W., Jenkins C., Eastwood P.R., Jarreta D., Kirsten A., Brooks D., Hillman D.R., Sant’Anna T., Meijer K., Dürr S., Rutten E.P., Kohler M., Probst V.S., Tal-Singer R., Gil E.G., den Brinker A.C., Leuppi J.D., Calverley P.M., Smeenk F.W., Costello R.W., Gramm M., Goldstein R., Groenen M.T., Magnussen H., Wouters, E.F., ZuWallack R.L., Amft O., Watz H., Spruit M. A. Physi cal activity patterns and clusters in 1001 patients with COPD. Chron. Respir. Dis. 2017;14(3):256–269. DOI: 10.1177/1479972316687207Mesquita R., Spina G., Pitta F., Donaire-Gonzalez D., Deering B.M., Patel M.S. , Mitchell K.E., Alison J., van Gestel A.J., Zogg S., Gagnon Ph., Abascal-Bolado B., Vagaggini B., Garcia-Ayme rich J., Jenkins S.C., Romme E.A., Kon S. S., Albert P.S., Waschki B., Shrikrishna D., Singh S.J., Hopkinson N.S., Miedinger D., Benzo R.P., Maltais F., Paggiaro P., McKeough Z.J., Polkey M.I., Hill K., Man W.D-C., Clarenbach C. F., Hernandes N.A., Savi D., Wootton S., Furlanetto K.C., Cindy Ng L.W., Vaes A.W., Jenkins C., Eastwood P.R., Jarreta D., Kirsten A., Brooks D., Hillman D.R., Sant’Anna T., Meijer K., Dürr S., Rutten E.P., Kohler M., Probst V.S., Tal-Singer R., Gil E.G., den Brinker A.C., Leuppi J.D., Calverley P.M., Smeenk F.W., Costello R.W., Gramm M., Goldstein R., Groenen M.T., Magnussen H., Wouters, E.F., ZuWallack R.L., Amft O., Watz H., Spruit M. A. Physi cal activity patterns and clusters in 1001 patients with COPD. Chron. Respir. Dis. 2017;14(3):256–269. DOI: 10.1177/1479972316687207Vogiatzis I., Nanas S., Roussos C. Interval training as an alternative modality to continuous exercise in patients with COPD. Eur. Respir. J. 2002;20:12–19. DOI: 10.1183/09031936.02.01152001Vogiatzis I., Nanas S., Roussos C. Interval training as an alternative modality to continuous exercise in patients with COPD. Eur. Respir. J. 2002;20:12–19. DOI: 10.1183/09031936.02.01152001Sillen M.J., Franssen F.M., Delbressine J.M., Vaes A.W., Wouters E.F.M., Spruit M.A. Effi cacy of lower-limb muscle training modalities in severely dyspnoeic individuals with COPD and Mesquita et al. 13 quadriceps muscle weakness: results from the DICES trial. Thorax. 2014;69:525–531. DOI: 10.1136/thoraxjnl-2013-204388Sillen M.J., Franssen F.M., Delbressine J.M., Vaes A.W., Wouters E.F.M., Spruit M.A. Effi cacy of lower-limb muscle training modalities in severely dyspnoeic individuals with COPD and Mesquita et al. 13 quadriceps muscle weakness: results from the DICES trial. Thorax. 2014;69:525–531. DOI: 10.1136/thoraxjnl-2013-204388Camillo C.A., Burtin C., Hornikx M., Demeyer H., De Bent K., van Remoortel H., Osadnik C.R., Janssens W., Troosters T. Physiological responses during downhill walking: A new exercise modality for subjects with chronic obstructive pulmonary disease? Chron. Respir. Dis. 2015;12:155–164. DOI: 10.1177/147997231557571Camillo C.A., Burtin C., Hornikx M., Demeyer H., De Bent K., van Remoortel H., Osadnik C.R., Janssens W., Troosters T. Physiological responses during downhill walking: A new exercise modality for subjects with chronic obstructive pulmonary disease? Chron. Respir. Dis. 2015;12:155–164. DOI: 10.1177/147997231557571Spruit M.A., Augustin I.M.L., Vanfl eteren L.E., Janssen D.J.A., Gaff ron S., Pennings H.-J., Smeenk F., Pieters W., van den Bergh J.J.A.M., Michels A.-J., Groenen M.T.J., Rutten E.P.A., Wouters E.F.M., Franssen F.M.E. Diff erential response to pulmonary rehabilitation in COPD: multidimensional profi ling. Eur. Respir. J. 2015;46:1625–1635. DOI: 10.1183/13993003.00350-2015Spruit M.A., Augustin I.M.L., Vanfl eteren L.E., Janssen D.J.A., Gaff ron S., Pennings H.-J., Smeenk F., Pieters W., van den Bergh J.J.A.M., Michels A.-J., Groenen M.T.J., Rutten E.P.A., Wouters E.F.M., Franssen F.M.E. Diff erential response to pulmonary rehabilitation in COPD: multidimensional profi ling. Eur. Respir. J. 2015;46:1625–1635. DOI: 10.1183/13993003.00350-2015Donaire-Gonzalez D., Gimeno-antos E., Balcells E., de Batlle J., Ramon M.A., Rodriguez E., Farrero E., Benet M., Guerra S., Sauleda J., Ferrer A., Ferrer J., Barberà J.A., Rodriguez-Roisin R., Gea J., Agustí A., Antó J.M., Garcia-Aymerich J. Benefi ts of physical activity on COPD hospitalisation depend on intensity. Eur. Respir. J. 2015;46:1281–1289. DOI: 10.1183/13993003.01699-2014Donaire-Gonzalez D., Gimeno-antos E., Balcells E., de Batlle J., Ramon M.A., Rodriguez E., Farrero E., Benet M., Guerra S., Sauleda J., Ferrer A., Ferrer J., Barberà J.A., Rodriguez-Roisin R., Gea J., Agustí A., Antó J.M., Garcia-Aymerich J. Benefi ts of physical activity on COPD hospitalisation depend on intensity. Eur. Respir. J. 2015;46:1281–1289. DOI: 10.1183/13993003.01699-2014Chan S.M.H., Selemidis S., Bozinovski S., Vlahos R. Pathobiological mechanisms underlying metabolic syndrome (MetS) in Chronic Obstructive Pulmonary Disease (COPD): clinical signifi cance and therapeutic strategies. Pharmacol. Ther. 2019;198:160–88. DOI: 10.1016/j.pharmthera.2019.02.013Chan S.M.H., Selemidis S., Bozinovski S., Vlahos R. Pathobiological mechanisms underlying metabolic syndrome (MetS) in Chronic Obstructive Pulmonary Disease (COPD): clinical signifi cance and therapeutic strategies. Pharmacol. Ther. 2019;198:160–88. DOI: 10.1016/j.pharmthera.2019.02.013Sepúlveda-Loyola W., Osadnik C., Phu S., Morita A.A., Duque G., Probst V.S. Diagnosis, prevalence, and clinical impact of Sarcopenia in COPD: a systematic review and meta-analysis. J. Cachexia Sarcopenia Muscle. 2020;11(5):1164–76. DOI: 10.1002/jcsm.12600Sepúlveda-Loyola W., Osadnik C., Phu S., Morita A.A., Duque G., Probst V.S. Diagnosis, prevalence, and clinical impact of Sarcopenia in COPD: a systematic review and meta-analysis. J. Cachexia Sarcopenia Muscle. 2020;11(5):1164–76. DOI: 10.1002/jcsm.12600Sayer A.A., Cruz-Jentoft A. Sarcopenia defi nition, diagnosis and treatment: consensus is growing. Age Ageing. 2022;51(10):afac220. DOI: 10.1093/ageing/afac220Sayer A.A., Cruz-Jentoft A. Sarcopenia defi nition, diagnosis and treatment: consensus is growing. Age Ageing. 2022;51(10):afac220. DOI: 10.1093/ageing/afac220Cruz-Jentoft A.J., Bahat G., Bauer J., Boirie Y., Bruyère O., Cederholm T., Cooper C., Landi F., Rolland Y., Sayer A.A., Schneider S.M., Sieber C.C., Topinkova E., Vandewoude M., Visser M., Zamboni M. Sarcopenia: revised European consensus on defi nition and diagnosis. Age Ageing. 2019;48(1):16–31. DOI: 10.1093/ageing/afy169Cruz-Jentoft A.J., Bahat G., Bauer J., Boirie Y., Bruyère O., Cederholm T., Cooper C., Landi F., Rolland Y., Sayer A.A., Schneider S.M., Sieber C.C., Topinkova E., Vandewoude M., Visser M., Zamboni M. Sarcopenia: revised European consensus on defi nition and diagnosis. Age Ageing. 2019;48(1):16–31. DOI: 10.1093/ageing/afy169Wang Z., Zhou X., Deng M., Yin Y., Li Y., Zhang Q., Bian Y., Miao J., Li J., Hou G. Clinical Impacts of Sarcopenic Obesity On Chro nic Obstructive Pulmonary Disease: a Cross-sectional Study. BMC Pulm. Med. 2023;23(1):394. DOI: 10.1186/s12890-023-02702-2Wang Z., Zhou X., Deng M., Yin Y., Li Y., Zhang Q., Bian Y., Miao J., Li J., Hou G. Clinical Impacts of Sarcopenic Obesity On Chro nic Obstructive Pulmonary Disease: a Cross-sectional Study. BMC Pulm. Med. 2023;23(1):394. DOI: 10.1186/s12890-023-02702-2Sanchez-Rodriguez D., Marco E, Cruz-Jentoft A.J. Defi ning sarcopenia: some caveats and challenges. Curr. Opin. Clin. Nutr. Metab. Care. 2020;23:127–32. DOI: 10.1097/MCO.0000000000000621Sanchez-Rodriguez D., Marco E, Cruz-Jentoft A.J. Defi ning sarcopenia: some caveats and challenges. Curr. Opin. Clin. Nutr. Metab. Care. 2020;23:127–32. DOI: 10.1097/MCO.0000000000000621Wu Z., Yang D., Ge Z., Yan M., Wu N., Liu Y. Body mass index of patients with chronic obstructive pulmonary disease is associated with pulmonary function and exacerbations: a retrospective real world research. J. Thorac. Dis. 2018;10(8):5086–5099. DOI: 10.21037/jtd.2018.08.67Wu Z., Yang D., Ge Z., Yan M., Wu N., Liu Y. Body mass index of patients with chronic obstructive pulmonary disease is associated with pulmonary function and exacerbations: a retrospective real world research. J. Thorac. Dis. 2018;10(8):5086–5099. DOI: 10.21037/jtd.2018.08.67Chan S.M.H., Selemidis S., Bozinovski S., Vlahos R. Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical signifi cance and therapeutic strategies. Pharmacol. Ther. 2019;198:160–188. DOI: 10.1016/j.pharmthera.2019.02.013Chan S.M.H., Selemidis S., Bozinovski S., Vlahos R. Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical signifi cance and therapeutic strategies. Pharmacol. Ther. 2019;198:160–188. DOI: 10.1016/j.pharmthera.2019.02.013Uchida A., Sakaue K., Inoue H. Epidemiology of asthma-chronic obstructive pulmonary disease overlap (ACO). Allergol. Int. 2018;67(2):165–171. DOI: 10.1016/j.alit.2018.02.002.Uchida A., Sakaue K., Inoue H. Epidemiology of asthma-chronic obstructive pulmonary disease overlap (ACO). Allergol. Int. 2018;67(2):165–171. DOI: 10.1016/j.alit.2018.02.002.Milne S., Mannino D., Sin D.D. Asthma-COPD overlap and chronic airfl ow obstruction: defi nitions, management, and unanswered questions. J. Allergy Clin. Immunol. Prac. 2020;8(2):483–495. DOI: 10.1016/j.jaip.2019.10.044Milne S., Mannino D., Sin D.D. Asthma-COPD overlap and chronic airfl ow obstruction: defi nitions, management, and unanswered questions. J. Allergy Clin. Immunol. Prac. 2020;8(2):483–495. DOI: 10.1016/j.jaip.2019.10.044Pahus L., Burgel P.R., Roche N., Paillasseur J.L., Chanez P. Randomized controlled trials of pharmacological treatments to prevent COPD exacerbations: applicability to real-life patients. BMC Pulm. Med. 2019;19(1):127. DOI: 10.1186/s12890-019-0882-yPahus L., Burgel P.R., Roche N., Paillasseur J.L., Chanez P. Randomized controlled trials of pharmacological treatments to prevent COPD exacerbations: applicability to real-life patients. BMC Pulm. Med. 2019;19(1):127. DOI: 10.1186/s12890-019-0882-yCarolan B.J., Sutherland E.R. Clinical phenotypes of chronic obstructive pulmonary disease and asthma: Recent advances. J. Allergy Clin. Immunol. 2013;131(3):627–34; quiz 635. DOI: 10.1016/j.jaci.2013.01.010Carolan B.J., Sutherland E.R. Clinical phenotypes of chronic obstructive pulmonary disease and asthma: Recent advances. J. Allergy Clin. Immunol. 2013;131(3):627–34; quiz 635. DOI: 10.1016/j.jaci.2013.01.010Fingleton J., Huang K., Weatherall M., Guo Y., Ivanov S., Bruijnzeel P., Zhang H., Wang W., Beasley R., Wang C. Phenotypes of symptomatic airways disease in China and New Zealand. Eur. Respir. J. 2017;50(6):1700957. DOI: 10.1183/13993003.00957-2017.SFingleton J., Huang K., Weatherall M., Guo Y., Ivanov S., Bruijnzeel P., Zhang H., Wang W., Beasley R., Wang C. Phenotypes of symptomatic airways disease in China and New Zealand. Eur. Respir. J. 2017;50(6):1700957. DOI: 10.1183/13993003.00957-2017.SReddel H.K., de Verdier M.G., Agustí A., Anderson G., Beasley R., Bel E.H., Janson C., Make B., Martin R.J., Pavord I., Price D., Keen C., Gardev A., Rennard S., Sveréus A., Bansal A.T., Brannman L., Karlsson N., Nuevo J., Nyberg F., Young S.S., Vestbo J. Prospective observational study in patients with obstructive lung disease: NOVELTY design. ERJ Open Res. 2019;5(1):00036–2018. DOI: 10.1183/23120541.00036-2018Reddel H.K., de Verdier M.G., Agustí A., Anderson G., Beasley R., Bel E.H., Janson C., Make B., Martin R.J., Pavord I., Price D., Keen C., Gardev A., Rennard S., Sveréus A., Bansal A.T., Brannman L., Karlsson N., Nuevo J., Nyberg F., Young S.S., Vestbo J. Prospective observational study in patients with obstructive lung disease: NOVELTY design. ERJ Open Res. 2019;5(1):00036–2018. DOI: 10.1183/23120541.00036-2018Reddel H.K., Vestbo J., Agustí A., Anderson G.P., Bansal A.T., Beasley R., Bel E.H., Janson C., Make B., Pavord I.D., Price D., Rapsomaniki E., Karlsson N., Finch D.K., Nuevo J., de Giorgio-Miller A., Alacqua M., Hughes R., Müllerová H., de Verdier M.G. Heterogeneity within and between physician-diagnosed asthma and/ or COPD: NOVELTY cohort. Eur. Respir. J. 2021;58(3):2003927. DOI: 10.1183/13993003.03927-2020Reddel H.K., Vestbo J., Agustí A., Anderson G.P., Bansal A.T., Beasley R., Bel E.H., Janson C., Make B., Pavord I.D., Price D., Rapsomaniki E., Karlsson N., Finch D.K., Nuevo J., de Giorgio-Miller A., Alacqua M., Hughes R., Müllerová H., de Verdier M.G. Heterogeneity within and between physician-diagnosed asthma and/ or COPD: NOVELTY cohort. Eur. Respir. J. 2021;58(3):2003927. DOI: 10.1183/13993003.03927-2020Hughes R., Rapsomaniki E., Janson C., Keen C., Make B.J., Burgel P.R., Tomaszewski E.L., Müllerová H., Reddel H.K. Frequent productive cough: symptom burden and future exacerbation risk among patients with asthma and/or COPD in the NOVELTY study. Respir. Med. 2022;200:106921. DOI: 10.1016/j.rmed.2022.106921Hughes R., Rapsomaniki E., Janson C., Keen C., Make B.J., Burgel P.R., Tomaszewski E.L., Müllerová H., Reddel H.K. Frequent productive cough: symptom burden and future exacerbation risk among patients with asthma and/or COPD in the NOVELTY study. Respir. Med. 2022;200:106921. DOI: 10.1016/j.rmed.2022.106921Agustí A., Rapsomaniki E., Beasley R., Hughes R., Müllerová H., Papi A., Pavord I.D., van den Berge M., Faner R. Treatable traits in the NOVELTY study. Respirology. 2022;27(11):929–940. DOI: 10.1111/resp.14325Agustí A., Rapsomaniki E., Beasley R., Hughes R., Müllerová H., Papi A., Pavord I.D., van den Berge M., Faner R. Treatable traits in the NOVELTY study. Respirology. 2022;27(11):929–940. DOI: 10.1111/resp.14325Hughes R., Rapsomaniki E., Bansal A.T., Vestbo J., Price D., Agustí A., Beasley R., Fageras M., Alacqua M., Papi A., Müllerová H., Reddel H.K. Cluster Analyses From the Real-World NOVELTY Study: Six Clusters Across the Asthma-COPD Spectrum. J. Allergy Clin. Immunol. Pract. 2023;11(9):2803–2811. DOI: 10.1016/j.jaip.2023.05.013Hughes R., Rapsomaniki E., Bansal A.T., Vestbo J., Price D., Agustí A., Beasley R., Fageras M., Alacqua M., Papi A., Müllerová H., Reddel H.K. Cluster Analyses From the Real-World NOVELTY Study: Six Clusters Across the Asthma-COPD Spectrum. J. Allergy Clin. Immunol. Pract. 2023;11(9):2803–2811. DOI: 10.1016/j.jaip.2023.05.013David B., Bafadhel M., Koenderman L., De Soyza A. Eosinophilic infl ammation in COPD: from an infl ammatory marker to a treatable trait. Thorax. 2021;76(2):188–195. DOI: 10.1136/thoraxjnl-2020-215167David B., Bafadhel M., Koenderman L., De Soyza A. Eosinophilic infl ammation in COPD: from an infl ammatory marker to a treatable trait. Thorax. 2021;76(2):188–195. DOI: 10.1136/thoraxjnl-2020-215167Papaporfyriou A., Bakakos P., Hillas G., Papaioannou A.I., Loukides S. Blood eosinophils in COPD: friend or foe? Expert Rev. Respir. Med. 2022;16(1):35–41. DOI: 10.1080/17476348.2021.2011219Papaporfyriou A., Bakakos P., Hillas G., Papaioannou A.I., Loukides S. Blood eosinophils in COPD: friend or foe? Expert Rev. Respir. Med. 2022;16(1):35–41. DOI: 10.1080/17476348.2021.2011219Kang H.S., Kim SK., Kim YH, Kim J.W., Lee S.H., Yoon H.K., Rhee C.K. The association between eosinophilic exacerbation and eosinophilic levels in stable COPD. BMC Pulm. Med. 2021;21(1):74. DOI: 10.1186/s12890-021-01443-4Kang H.S., Kim SK., Kim YH, Kim J.W., Lee S.H., Yoon H.K., Rhee C.K. The association between eosinophilic exacerbation and eosinophilic levels in stable COPD. BMC Pulm. Med. 2021;21(1):74. DOI: 10.1186/s12890-021-01443-4Segal L.N., Martinez F.J. Chronic obstructive pulmonary disease subpopulations and phenotyping. J. Allergy Clin. Immunol. 2018;141(6):1961–1971. DOI: 10.1016/j.jaci.2018.02.035Segal L.N., Martinez F.J. Chronic obstructive pulmonary disease subpopulations and phenotyping. J. Allergy Clin. Immunol. 2018;141(6):1961–1971. DOI: 10.1016/j.jaci.2018.02.035Uwagboe I., Adcock I.M., Bello F.L., Caramori G., Mumby S. New drugs under development for COPD. Minerva Med. 2022;113(3):471– 496. DOI: 10.23736/S0026-4806.22.08024-7Uwagboe I., Adcock I.M., Bello F.L., Caramori G., Mumby S. New drugs under development for COPD. Minerva Med. 2022;113(3):471– 496. DOI: 10.23736/S0026-4806.22.08024-7Trinkmann F., Schaefer J., Gawlitza J., Drayss J., Schroeter M., Michels J.D., Akin I., Borggrefe M., Saur J. COPD phenotyping and diff erential therapy can be improved using impulse oscillometry and multiple breath washout testing. American journal of respiratory and critical care medicine. 2019;199(9). DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A2409Trinkmann F., Schaefer J., Gawlitza J., Drayss J., Schroeter M., Michels J.D., Akin I., Borggrefe M., Saur J. COPD phenotyping and diff erential therapy can be improved using impulse oscillometry and multiple breath washout testing. American journal of respiratory and critical care medicine. 2019;199(9). DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A2409

The authors declare that there are no conflicts of interest present.